ESWI Board Florian Krammer is a virologist and vaccine developer. In his podcast viroLOGICAL he will talk about viruses on a weekly basis – from historical pandemics to current developments.

The ESCMID Vaccine Study Group (EVASG) is conducting a study aimed at understanding which barriers and interventions healthcare professionals consider most important for improving influenza vaccination uptake among healthcare workers.

Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is a rare prothrombotic complication that occurs after adenoviral vector–based vaccination against coronavirus disease 2019.

The association between influenza vaccination and the risk of myocardial infarction (MI) remains incompletely characterized, particularly in real-world populations.

In a pre-season influenza risk assessment publicly posted in October 2025, Canadian investigators used global genomic and antigenic surveillance data to highlight important mutations in circulating influenza A(H3N2) viruses.

Both viral and host factors have contributed to the intensity of influenza activity during the 2025–2026 season. Some of these factors can be managed, whereas others are largely beyond human control.

To investigate indirect vaccine effectiveness (indirVE) of vaccination of children and adolescents with seasonal influenza vaccines against influenza-related outcomes occurring in other population groups.

Baloxavir marboxil, a cap-dependent endonuclease inhibitor, was approved in Japan in February 2018 for treatment of influenza A and B infections, making Japan the first country to introduce its clinical use.